Credit: Shutterstock photoWright Medical Group N.V. (WMGI) recently highlighted its latest innovations at the American College of Foot and Ankle Surgeons (ACFAS) 2018 Scientific Conference in Nashville, Tennessee. The featured products include the INVISION Total Ankle Revision System and ORTHOLOC 3Di Ankle Fracture Low Profile System.
INVISION Total Ankle Revision System
The Amsterdam-based orthopedic medical device company has exhibited its full range of lower extremities and biologic solutions, including the INVISION Total Ankle Revision System with PROPHECY Preoperative Navigation. Notably, PROPHECY is the first preoperative planning system with patient-specific instrumentation for ankle revision arthroplasty which received its first approval in 2012. It aims to extend the use of preoperative planning through revision procedures by offering innovative tools to physicians, leading to improved patient outcomes.
The key benefits of the system include a full line-up of implants that cater to the patients' needs, the ability to create a detailed revision surgical plan with or without failed implants and the 3D visualization of bone-loss management and reconstruction of joint height under unique revision conditions.
Per management, performing revision procedures of failed total ankle arthroplasty poses a significant challenge. PROPHECY is capable of planning out such cases preoperatively while determining appropriate alignment based on the individual patient's CT data.
ORTHOLOC 3Di Ankle Fracture Low Profile System
The ORTHOLOC system features a complete range of ankle fracture plates designed specifically for the foot and ankle surgeons. The system features low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw technology, providing an innovative fracture solution, addressing variations in fracture patterns and anatomy.
Market Trends
Per a study conducted by BIS Research, the global orthopedic devices market is expected to reach $61.02 billion by the end of 2023, growing at a CAGR of 6.1% from 2016. Growing prevalence of various orthopedic disorders and increasing geriatric population are the major growth drivers.
Hence, it can be deduced that the move to introduce a new product portfolio by Wright Medical has been strategic and timely, which is likely to expand leadership in the global orthopedic industry.
Price Performance
In the past six months, Wright Medical has underperformed the industry in terms of price. The stock has lost 24.9% versus the industry's gain of 7.6%.
Zacks Rank and Key Picks
Wright Medical carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are athenahealth, Inc. (ATHN), Bio-Rad Laboratories, Inc. (BIO) and Centene Corporation (CNC). Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
athenahealth has expected long-term growth rate of 17.7% and earnings per share growth rate of 21.5%.
Bio-Rad has expected long-term growth rate of 20% and earnings per share growth rate of 20%.
Centene has expected long-term growth rate of 14.4% and earnings per share growth rate of 14.4%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Wright Medical Group N.V. (WMGI) recently highlighted its latest innovations at the American College of Foot and Ankle Surgeons (ACFAS) 2018 Scientific Conference in Nashville, Tennessee. The featured products include the INVISION Total Ankle Revision System and ORTHOLOC 3Di Ankle Fracture Low Profile System.
INVISION Total Ankle Revision System
The Amsterdam-based orthopedic medical device company has exhibited its full range of lower extremities and biologic solutions, including the INVISION Total Ankle Revision System with PROPHECY Preoperative Navigation. Notably, PROPHECY is the first preoperative planning system with patient-specific instrumentation for ankle revision arthroplasty which received its first approval in 2012. It aims to extend the use of preoperative planning through revision procedures by offering innovative tools to physicians, leading to improved patient outcomes.
The key benefits of the system include a full line-up of implants that cater to the patients' needs, the ability to create a detailed revision surgical plan with or without failed implants and the 3D visualization of bone-loss management and reconstruction of joint height under unique revision conditions.
Per management, performing revision procedures of failed total ankle arthroplasty poses a significant challenge. PROPHECY is capable of planning out such cases preoperatively while determining appropriate alignment based on the individual patient's CT data.
ORTHOLOC 3Di Ankle Fracture Low Profile System
The ORTHOLOC system features a complete range of ankle fracture plates designed specifically for the foot and ankle surgeons. The system features low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw technology, providing an innovative fracture solution, addressing variations in fracture patterns and anatomy.
Market Trends
Per a study conducted by BIS Research, the global orthopedic devices market is expected to reach $61.02 billion by the end of 2023, growing at a CAGR of 6.1% from 2016. Growing prevalence of various orthopedic disorders and increasing geriatric population are the major growth drivers.
Hence, it can be deduced that the move to introduce a new product portfolio by Wright Medical has been strategic and timely, which is likely to expand leadership in the global orthopedic industry.
Price Performance
In the past six months, Wright Medical has underperformed the industry in terms of price. The stock has lost 24.9% versus the industry's gain of 7.6%.
Zacks Rank and Key Picks
Wright Medical carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are athenahealth, Inc. (ATHN), Bio-Rad Laboratories, Inc. (BIO) and Centene Corporation (CNC). Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
athenahealth has expected long-term growth rate of 17.7% and earnings per share growth rate of 21.5%.
Bio-Rad has expected long-term growth rate of 20% and earnings per share growth rate of 20%.
Centene has expected long-term growth rate of 14.4% and earnings per share growth rate of 14.4%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Wright Medical Group N.V. (WMGI) recently highlighted its latest innovations at the American College of Foot and Ankle Surgeons (ACFAS) 2018 Scientific Conference in Nashville, Tennessee. The featured products include the INVISION Total Ankle Revision System and ORTHOLOC 3Di Ankle Fracture Low Profile System.
INVISION Total Ankle Revision System
The Amsterdam-based orthopedic medical device company has exhibited its full range of lower extremities and biologic solutions, including the INVISION Total Ankle Revision System with PROPHECY Preoperative Navigation. Notably, PROPHECY is the first preoperative planning system with patient-specific instrumentation for ankle revision arthroplasty which received its first approval in 2012. It aims to extend the use of preoperative planning through revision procedures by offering innovative tools to physicians, leading to improved patient outcomes.
The key benefits of the system include a full line-up of implants that cater to the patients' needs, the ability to create a detailed revision surgical plan with or without failed implants and the 3D visualization of bone-loss management and reconstruction of joint height under unique revision conditions.
Per management, performing revision procedures of failed total ankle arthroplasty poses a significant challenge. PROPHECY is capable of planning out such cases preoperatively while determining appropriate alignment based on the individual patient's CT data.
ORTHOLOC 3Di Ankle Fracture Low Profile System
The ORTHOLOC system features a complete range of ankle fracture plates designed specifically for the foot and ankle surgeons. The system features low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw technology, providing an innovative fracture solution, addressing variations in fracture patterns and anatomy.
Market Trends
Per a study conducted by BIS Research, the global orthopedic devices market is expected to reach $61.02 billion by the end of 2023, growing at a CAGR of 6.1% from 2016. Growing prevalence of various orthopedic disorders and increasing geriatric population are the major growth drivers.
Hence, it can be deduced that the move to introduce a new product portfolio by Wright Medical has been strategic and timely, which is likely to expand leadership in the global orthopedic industry.
Price Performance
In the past six months, Wright Medical has underperformed the industry in terms of price. The stock has lost 24.9% versus the industry's gain of 7.6%.
Zacks Rank and Key Picks
Wright Medical carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are athenahealth, Inc. (ATHN), Bio-Rad Laboratories, Inc. (BIO) and Centene Corporation (CNC). Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
athenahealth has expected long-term growth rate of 17.7% and earnings per share growth rate of 21.5%.
Bio-Rad has expected long-term growth rate of 20% and earnings per share growth rate of 20%.
Centene has expected long-term growth rate of 14.4% and earnings per share growth rate of 14.4%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Wright Medical Group N.V. (WMGI) recently highlighted its latest innovations at the American College of Foot and Ankle Surgeons (ACFAS) 2018 Scientific Conference in Nashville, Tennessee. The featured products include the INVISION Total Ankle Revision System and ORTHOLOC 3Di Ankle Fracture Low Profile System.
INVISION Total Ankle Revision System
The Amsterdam-based orthopedic medical device company has exhibited its full range of lower extremities and biologic solutions, including the INVISION Total Ankle Revision System with PROPHECY Preoperative Navigation. Notably, PROPHECY is the first preoperative planning system with patient-specific instrumentation for ankle revision arthroplasty which received its first approval in 2012. It aims to extend the use of preoperative planning through revision procedures by offering innovative tools to physicians, leading to improved patient outcomes.
The key benefits of the system include a full line-up of implants that cater to the patients' needs, the ability to create a detailed revision surgical plan with or without failed implants and the 3D visualization of bone-loss management and reconstruction of joint height under unique revision conditions.
Per management, performing revision procedures of failed total ankle arthroplasty poses a significant challenge. PROPHECY is capable of planning out such cases preoperatively while determining appropriate alignment based on the individual patient's CT data.
ORTHOLOC 3Di Ankle Fracture Low Profile System
The ORTHOLOC system features a complete range of ankle fracture plates designed specifically for the foot and ankle surgeons. The system features low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw technology, providing an innovative fracture solution, addressing variations in fracture patterns and anatomy.
Market Trends
Per a study conducted by BIS Research, the global orthopedic devices market is expected to reach $61.02 billion by the end of 2023, growing at a CAGR of 6.1% from 2016. Growing prevalence of various orthopedic disorders and increasing geriatric population are the major growth drivers.
Hence, it can be deduced that the move to introduce a new product portfolio by Wright Medical has been strategic and timely, which is likely to expand leadership in the global orthopedic industry.
Price Performance
In the past six months, Wright Medical has underperformed the industry in terms of price. The stock has lost 24.9% versus the industry's gain of 7.6%.
Zacks Rank and Key Picks
Wright Medical carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are athenahealth, Inc. (ATHN), Bio-Rad Laboratories, Inc. (BIO) and Centene Corporation (CNC). Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
athenahealth has expected long-term growth rate of 17.7% and earnings per share growth rate of 21.5%.
Bio-Rad has expected long-term growth rate of 20% and earnings per share growth rate of 20%.
Centene has expected long-term growth rate of 14.4% and earnings per share growth rate of 14.4%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Wright Medical Group N.V.WMGI recently highlighted its latest innovations at the American College of Foot and Ankle Surgeons (ACFAS) 2018 Scientific Conference in Nashville, Tennessee. The featured products include the INVISION Total Ankle Revision System and ORTHOLOC 3Di Ankle Fracture Low Profile System.
INVISION Total Ankle Revision System
The Amsterdam-based orthopedic medical device company has exhibited its full range of lower extremities and biologic solutions, including the INVISION Total Ankle Revision System with PROPHECY Preoperative Navigation. Notably, PROPHECY is the first preoperative planning system with patient-specific instrumentation for ankle revision arthroplasty which received its first approval in 2012. It aims to extend the use of preoperative planning through revision procedures by offering innovative tools to physicians, leading to improved patient outcomes.
The key benefits of the system include a full line-up of implants that cater to the patients' needs, the ability to create a detailed revision surgical plan with or without failed implants and the 3D visualization of bone-loss management and reconstruction of joint height under unique revision conditions.
Per management, performing revision procedures of failed total ankle arthroplasty poses a significant challenge. PROPHECY is capable of planning out such cases preoperatively while determining appropriate alignment based on the individual patient's CT data.
ORTHOLOC 3Di Ankle Fracture Low Profile System
The ORTHOLOC system features a complete range of ankle fracture plates designed specifically for the foot and ankle surgeons. The system features low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw technology, providing an innovative fracture solution, addressing variations in fracture patterns and anatomy.
Market Trends
Per a study conducted by BIS Research, the global orthopedic devices market is expected to reach $61.02 billion by the end of 2023, growing at a CAGR of 6.1% from 2016. Growing prevalence of various orthopedic disorders and increasing geriatric population are the major growth drivers.
Hence, it can be deduced that the move to introduce a new product portfolio by Wright Medical has been strategic and timely, which is likely to expand leadership in the global orthopedic industry.
Price Performance
In the past six months, Wright Medical has underperformed the industry in terms of price. The stock has lost 25.7% versus the industry's gain of 7.2%.
However, such developments are likely to aid the company in the quarters ahead.
Zacks Rank and Key Picks
Wright Medical carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are athenahealth, Inc. ATHN , Bio-Rad Laboratories, Inc. BIO and Centene Corp. CNC . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
athenahealth has expected long-term growth rate of 17.7% and earnings per share growth rate of 21.5%.
Bio-Rad has expected long-term growth rate of 20% and earnings per share growth rate of 20%.
Centene has expected long-term growth rate of 14.4% and earnings per share growth rate of 14.4%.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
athenahealth, Inc. (ATHN): Free Stock Analysis Report
Wright Medical Group N.V. (WMGI): Free Stock Analysis Report
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
